Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: Functional similarities but mechanistic differences with the immunosuppressive drug rapamycin

Journal of Immunology

Volumn 160, Issue 5, 1998, Pages 2215-2222

  Boytim, Michelle L ^a   Lyu, Shu Chen ^a   Jung, Ron ^a   Krensky, Alan M ^a   Clayberger, Carol ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; CDC2-CDC28 KINASES; CELL CYCLE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; GROWTH INHIBITORS; HLA-DQ ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYENES; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE HOMOLOGY, AMINO ACID; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS; TIME FACTORS;

EID: 0032032267     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Germain, R. N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287.
2. Cammarota, G., A. Scheirle, B. Takacs, D. M. Doran, R. Knorr, W. Bannwarth, J. Guardiola, and F. Sinigaglia. 1992. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature 356:799.
3. Konig, R., L. Y. Huang, and R. N. Germain. 1992. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 156:796.
4. Nag, B., H. G. Wada, D. Passmore, B. R. Clark, S. D. Sharma, and H. M. McConnell. 1993. Purified β-chain of MHC class II binds to CD4 molecules on transfected HeLa cells. J. Immunol. 150:1158.
5. Clayberger, C., S. C. Lyu, R. DeKruyff, P. Parham, and A. M. Krensky. 1994. Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T lymphocyte immune responses in vitro. J. Immunol. 153:946.
6. Salter, R. D., R. J. Benjamin, P. K. Wesley, S. E. Buxton, T. P. Garrett, C. Clayberger, A. M. Krensky, A. M. Norment, D. R. Littman, and P. Parham. 1990. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 345:41.
7. Miller, J. F., and A. Basten. 1996. Mechanisms of tolerance to self. Curr. Opin. Immunol. 8:815.
8. Kruisbeek, A. M., and D. Amsen. 1996. Mechanisms underlying T-cell tolerance. Curr. Opin. Immunol. 8:233.
9. Lanier, L. L. 1997. Natural killer cell receptors and MHC class I interactions. Curr. Opin. Immunol. 9:126.
10. Lobo, P. I., M. Y. Chang, and E. Mellins. 1996. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis. Immunology 88:625.
11. Shoskes, D. A., and K. J. Wood. 1994. Indirect presentation of MHC antigens in transplantation. Immunol. Today 15:32.
12. Watschinger, B., L. Gallon, C. B. Carpenter, and M. H. Sayegh. 1994. Mechanisms of allo-recognition: recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 57:572.
13. Cochrum, K., D. Hanes, D. Potter, H. Perkins, W. Amend, F. Vincenti, Y. Iwaki, G. Opelz, P. Terasaki, B. Levin, D. Sampson, N. Feduska, and O. Salvatierra. 1981. Improved graft survival following donor-specitic blood transfusions. Transplant. Proc. 13:1657.
14. Madsen, J. C., K. J. Wood, R. A. Superina, and P. J. Morris. 1989. Induction of immunological unresponsiveness using recipient cells transfected with donor class I or class II MHC genes. Transplant. Proc. 21:477.
15. Foster, S., K. J. Wood, and P. J. Morris. 1989. Comparison of the effect of protein micelles containing purified class I MHC antigen and a cytosolic preparation containing water soluble class I molecules on rat renal allograft survival. Transplant. Proc. 21:375.
16. Pouteil, N. C., K. J. Wood, and P. J. Morris. 1993. The effect of purified class II major histocompatibility complex antigen on the survival of vascularized organ allografts in the rat. Transplantation 55:656.
17. Sayegh, M. H., S. J. Khoury, W. W. Hancock, H. L. Weiner, and C. B. Carpenter. 1993. Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant. Proc. 25:357.
18. Sayegh, M. H., N. Perico, O. Imberti, W. W. Hancock, C. B. Carpenter, and G. Remuzzi. 1993. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. Transplantation 56:461.
19. Murphy, B., E. Akalin, B. Watschinger, C. B. Carpenter, and M. H. Sayegh. 1995. Inhibition of the alloimmune response with synthetic nonpolymorphic class II MHC peptides. Transplant. Proc. 27:409.
20. Parham, P., C. Clayberger, S. L. Zorn, D. S. Ludwig, G. K. Schoolnik, and A. M. Krensky. 1987. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2. Nature 325:625.
21. Clayberger, C., P. Parham, J. Rothbard, D. S. Ludwig, G. K. Schoolnik, and A. M. Krensky. 1987. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 330:763.
22. Nossner, E. J. E. Goldberg, C. Naftzger, S. C. Lyu, C. Clayberger, and A. M. Krensky. 1996. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J. Exp. Med. 183:339.
23. Buelow, R., P. Veyron, C. Clayberger, P. Pouletty, and J. L. Touraine. 1995. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. Transplantation 59:455.
24. Woo, J., L. Gao, M. C. Cornejo, and R. Buelow. 1995. A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Transplantation 60:1156.
25. Hanaway, M. J., E. K. Geissler, J. Wang, J. J. Fechner, R. Buelow, and S. J. Knechtle. 1996. Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. Transplantation 61:1222.
26. Clayberger, C., S. C. Lyu, P. Pouletty, and A. M. Krensky. 1993. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transplant. Proc. 25:477.
27. + T cells requires repeated antigenic stimulation. Cell. Immunol. 152:18.
28. Firpo, E. J., A. Koff, M. J. Solomon, and J. M. Roberts. 1994. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol. 14:4889.
29. Dumont, F. J., M. J. Staruch, S. L. Koprak, M. R. Melino, and N. H. Sigal. 1990. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144:251.
30. Morice, W. G., G. Wiederrecht, G. J. Brunn, J. J. Siekierka, and R. T. Abraham. 1993. Rapamycin inhibition of interleukin-2-dependent P33cdk2 and p34cdc2 kinase activation in T lymphocytes. J. Biol. Chem. 268:22737.
31. 1/S-phase growth arrest in T lymphocytes. J. Biol. Chem. 268:3734.
32. Marsh, S. G., and J. G. Bodmer. 1993. HLA class II nucleotide sequences, 1992. Immunogenetics 37:79.
33. Brown, J. H., T. Jardetzky, M. A. Saper, B. Samraoui, P. J. Bjorkman, and D. C. Wiley. 1988. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 332:845.
34. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:31.
35. Fruman, D. A., S. J. Burakoff, and B. E. Bierer. 1994. Immunophilins in protein folding and immunosuppression. FASEB J. 8:391.
36. Tocci, M. J., D. A. Matkovich, K. A. Collier, P. Kwok, F. Dumont, S. Lin, S. Degudicibus, J. J. Siekierka, J. Chin, and N. I. Hutchinson. 1989. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143:718.
37. Deshaies, R. J. 1995. The self-destructive personality of a cell cycle in transition. Curr. Opin. Cell Biol. 7:781.
38. Grana, X., and E. P. Reddy. 1995. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211.
39. Nourse, J., E. Firpo, W. M. Flanagan, S. Coats, K. Polyak, M. H. Lee, J. Massague, G. R. Crabtree, and J. M. Roberts. 1994. Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570.
40. 1 prolongation in mitogen-activated T lymphocytes. J. Immunol. 155:3418.
41. Dumont, F. J., M. R. Melino, M. J. Staruch, S. L. Koprak, P. A. Fischer, and N. H. Sigal. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J. Immunol. 144:1418.
42. Nisco, S., P. Vriens, G. Hoyt, S. C. Lyu, F. Farfan, P. Pouletty, A. M. Krensky, and C. Clayberger. 1994. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J. Immunol. 152:3786.
43. Chicz, R. M., W. S. Lane, R. A. Robinson, M. Trucco, J. L. Strominger, and J. C. Gorga. 1994. Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. Int. Immunol. 6:1639.
44. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
45. Mondino, A., and M. K. Jenkins. 1994. Surface proteins involved in T cell costimulation. J. Leukocyte Biol. 55:805.
46. Lobo, P. I., M. Y. Chang, and B. Mellins. 1996. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis. Immunology 88:625.
47. Lobo, P. I., and H. C. Patel. 1994. A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells. Immunology 83:240.
48. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682.
49. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905.
50. Beretta, L., A. C. Gingras, Y. V. Svitkin, M. N. Hall, and N. Sonenberg. 1996. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15:658.
51. Brown, E. J., P. A. Beal, C. T. Keith, J. Chen, T. B. Shin, and S. L. Schreiber. 1995. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441.
52. Feuerstein, N., D. Huang, and M. B. Prystowsky. 1995. Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte: evidence for inhibition of CREB/ATF binding activities. J. Biol. Chem. 270:9454.
53. Krangel, M. S. 1986. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J. Exp. Med. 163:1173.
54. Kamada, N. 1985. The immunology of experimental liver transplantation in the rat. Imnunology 55:369.
55. Claus, R., H. Werner, H. A. Schulze, H. Walzel, and H. Friemel. 1990. Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity? Immunol. Lett. 26:203.
56. Puppo, F., M. Scudeletti, F. Indiveri, and S. Ferrone. 1995. Serum HLA class I antigens: markers and modulators of an immune response? Immunol. Today 16: 124.
57. Blumberg, N., D. J. Triulzi, and J. M. Heal. 1990. Transfusion-induced immunomodulation and its clinical consequences. Transfus. Med. Rev. 4:24.
58. Opelz, G., and P. I. Terasaki. 1978 Improvement of kidney-graft survival with increased numbers of blood transfusions. N. Engl. J. Med. 299:799.
59. Kronenberg, M., M. Steinmetz, J. Kobori, C. Kraig, J. A. Kapp, C. W. Pierce, C. M. Sorensen, G. Suzuki, T. Tada, and L. Hood. 1983. RNA transcripts for I-J polypeptidcs are apparently not encoded between the I-A and I-E subregions of the murine major histocompatibility complex. Proc. Natl. Acad. Sci. USA 80: 5704.